Which has stronger earnings & valuation, CGON or NBTX?

Nanobiotix has higher revenue and earnings than CG Oncology. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CG Oncology $4.04M 1,533.38 -$160.99M -$2.69 N/A Nanobiotix $36.87M 38.80 -$27.11M N/A N/A

Does the media prefer CGON or NBTX?

In the previous week, Nanobiotix had 7 more articles in the media than CG Oncology. MarketBeat recorded 9 mentions for Nanobiotix and 2 mentions for CG Oncology. CG Oncology's average media sentiment score of 1.45 beat Nanobiotix's score of 0.31 indicating that CG Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CG Oncology 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nanobiotix 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings & valuation, LGND or NBTX?

Ligand Pharmaceuticals has higher revenue and earnings than Nanobiotix. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Ligand Pharmaceuticals $268.09M 22.73 $124.45M $9.35 32.69 Nanobiotix $36.87M 38.80 -$27.11M N/A N/A

Does the media prefer LGND or NBTX?

In the previous week, Ligand Pharmaceuticals had 3 more articles in the media than Nanobiotix. MarketBeat recorded 12 mentions for Ligand Pharmaceuticals and 9 mentions for Nanobiotix. Nanobiotix's average media sentiment score of 0.31 beat Ligand Pharmaceuticals' score of 0.23 indicating that Nanobiotix is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ligand Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Nanobiotix 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings and valuation, GRAL or NBTX?

Nanobiotix has lower revenue, but higher earnings than GRAIL. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GRAIL $147.17M 41.39 -$408.35M -$9.75 N/A Nanobiotix $36.87M 38.80 -$27.11M N/A N/A

Is GRAL or NBTX more profitable?

Nanobiotix has a net margin of 0.00% compared to GRAIL's net margin of -236.95%. Nanobiotix's return on equity of 0.00% beat GRAIL's return on equity. Company Net Margins Return on Equity Return on Assets GRAIL -236.95% -15.88% -14.02% Nanobiotix N/A N/A N/A

Does the media prefer GRAL or NBTX?

In the previous week, GRAIL had 6 more articles in the media than Nanobiotix. MarketBeat recorded 15 mentions for GRAIL and 9 mentions for Nanobiotix. GRAIL's average media sentiment score of 0.45 beat Nanobiotix's score of 0.31 indicating that GRAIL is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GRAIL 4 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Nanobiotix 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings & valuation, NBTX or KNSA?

Kiniksa Pharmaceuticals International has higher revenue and earnings than Nanobiotix. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nanobiotix $36.87M 38.80 -$27.11M N/A N/A Kiniksa Pharmaceuticals International $677.56M 8.70 $59.01M $0.97 77.89

Which has higher earnings & valuation, SRRK or NBTX?

Nanobiotix has higher revenue and earnings than Scholar Rock. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Scholar Rock N/A N/A -$377.94M -$3.45 N/A Nanobiotix $36.87M 38.80 -$27.11M N/A N/A

Is SRRK or NBTX more profitable?

Nanobiotix's return on equity of 0.00% beat Scholar Rock's return on equity. Company Net Margins Return on Equity Return on Assets Scholar Rock N/A -160.19% -87.18% Nanobiotix N/A N/A N/A

Does the media prefer SRRK or NBTX?

In the previous week, Nanobiotix had 5 more articles in the media than Scholar Rock. MarketBeat recorded 9 mentions for Nanobiotix and 4 mentions for Scholar Rock. Scholar Rock's average media sentiment score of 0.46 beat Nanobiotix's score of 0.31 indicating that Scholar Rock is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Scholar Rock 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Nanobiotix 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Nanobiotix (NBTX) Competitors

$28.26 -2.90 (-9.31%)

As of 02:47 PM Eastern

Compare

NBTX vs. CGON, LGND, GRAL, KNSA, and SRRK

Should you buy Nanobiotix stock or one of its competitors? Nanobiotix's main competitors and comparable companies include CG Oncology (CGON), Ligand Pharmaceuticals (LGND), GRAIL (GRAL), Kiniksa Pharmaceuticals International (KNSA), and Scholar Rock (SRRK). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Nanobiotix compare to CG Oncology?

CG Oncology (NASDAQ:CGON) and Nanobiotix (NASDAQ:NBTX) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, media sentiment, analyst recommendations, earnings, risk and institutional ownership.

Nanobiotix has higher revenue and earnings than CG Oncology.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CG Oncology	$4.04M	1,533.38	-$160.99M	-$2.69	N/A
Nanobiotix	$36.87M	38.80	-$27.11M	N/A	N/A

CG Oncology has a beta of 0.24, indicating that its share price is 76% less volatile than the broader market. Comparatively, Nanobiotix has a beta of 0.81, indicating that its share price is 19% less volatile than the broader market.

In the previous week, Nanobiotix had 7 more articles in the media than CG Oncology. MarketBeat recorded 9 mentions for Nanobiotix and 2 mentions for CG Oncology. CG Oncology's average media sentiment score of 1.45 beat Nanobiotix's score of 0.31 indicating that CG Oncology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CG Oncology	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nanobiotix	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

26.6% of CG Oncology shares are owned by institutional investors. Comparatively, 38.8% of Nanobiotix shares are owned by institutional investors. 4.8% of CG Oncology shares are owned by company insiders. Comparatively, 3.5% of Nanobiotix shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Nanobiotix has a net margin of 0.00% compared to CG Oncology's net margin of -3,602.68%. Nanobiotix's return on equity of 0.00% beat CG Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CG Oncology	-3,602.68%	-25.20%	-23.98%
Nanobiotix	N/A	N/A	N/A

CG Oncology currently has a consensus target price of $87.78, suggesting a potential upside of 25.60%. Nanobiotix has a consensus target price of $46.67, suggesting a potential upside of 65.13%. Given Nanobiotix's higher possible upside, analysts plainly believe Nanobiotix is more favorable than CG Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CG Oncology	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
Nanobiotix	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Nanobiotix beats CG Oncology on 9 of the 14 factors compared between the two stocks.

How does Nanobiotix compare to Ligand Pharmaceuticals?

Ligand Pharmaceuticals (NASDAQ:LGND) and Nanobiotix (NASDAQ:NBTX) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, valuation, institutional ownership, risk, dividends, earnings and analyst recommendations.

Ligand Pharmaceuticals has a beta of 1.11, meaning that its share price is 11% more volatile than the broader market. Comparatively, Nanobiotix has a beta of 0.81, meaning that its share price is 19% less volatile than the broader market.

Ligand Pharmaceuticals has a net margin of 67.88% compared to Nanobiotix's net margin of 0.00%. Ligand Pharmaceuticals' return on equity of 20.06% beat Nanobiotix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ligand Pharmaceuticals	67.88%	20.06%	11.68%
Nanobiotix	N/A	N/A	N/A

91.3% of Ligand Pharmaceuticals shares are held by institutional investors. Comparatively, 38.8% of Nanobiotix shares are held by institutional investors. 5.6% of Ligand Pharmaceuticals shares are held by company insiders. Comparatively, 3.5% of Nanobiotix shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Ligand Pharmaceuticals has higher revenue and earnings than Nanobiotix.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ligand Pharmaceuticals	$268.09M	22.73	$124.45M	$9.35	32.69
Nanobiotix	$36.87M	38.80	-$27.11M	N/A	N/A

In the previous week, Ligand Pharmaceuticals had 3 more articles in the media than Nanobiotix. MarketBeat recorded 12 mentions for Ligand Pharmaceuticals and 9 mentions for Nanobiotix. Nanobiotix's average media sentiment score of 0.31 beat Ligand Pharmaceuticals' score of 0.23 indicating that Nanobiotix is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ligand Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Nanobiotix	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Ligand Pharmaceuticals currently has a consensus price target of $337.89, indicating a potential upside of 10.56%. Nanobiotix has a consensus price target of $46.67, indicating a potential upside of 65.13%. Given Nanobiotix's higher possible upside, analysts plainly believe Nanobiotix is more favorable than Ligand Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ligand Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	3.00
Nanobiotix	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Ligand Pharmaceuticals beats Nanobiotix on 11 of the 14 factors compared between the two stocks.

How does Nanobiotix compare to GRAIL?

GRAIL (NASDAQ:GRAL) and Nanobiotix (NASDAQ:NBTX) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, institutional ownership, earnings, analyst recommendations, valuation and dividends.

GRAIL has a beta of 3.25, meaning that its stock price is 225% more volatile than the broader market. Comparatively, Nanobiotix has a beta of 0.81, meaning that its stock price is 19% less volatile than the broader market.

Nanobiotix has lower revenue, but higher earnings than GRAIL.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GRAIL	$147.17M	41.39	-$408.35M	-$9.75	N/A
Nanobiotix	$36.87M	38.80	-$27.11M	N/A	N/A

38.8% of Nanobiotix shares are held by institutional investors. 1.8% of GRAIL shares are held by company insiders. Comparatively, 3.5% of Nanobiotix shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, GRAIL had 6 more articles in the media than Nanobiotix. MarketBeat recorded 15 mentions for GRAIL and 9 mentions for Nanobiotix. GRAIL's average media sentiment score of 0.45 beat Nanobiotix's score of 0.31 indicating that GRAIL is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GRAIL	4 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Nanobiotix	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

GRAIL currently has a consensus price target of $93.60, indicating a potential downside of 31.36%. Nanobiotix has a consensus price target of $46.67, indicating a potential upside of 65.13%. Given Nanobiotix's stronger consensus rating and higher possible upside, analysts plainly believe Nanobiotix is more favorable than GRAIL.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GRAIL	1 Sell rating(s)	6 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.33
Nanobiotix	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Nanobiotix has a net margin of 0.00% compared to GRAIL's net margin of -236.95%. Nanobiotix's return on equity of 0.00% beat GRAIL's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GRAIL	-236.95%	-15.88%	-14.02%
Nanobiotix	N/A	N/A	N/A

Summary

Nanobiotix beats GRAIL on 8 of the 14 factors compared between the two stocks.

How does Nanobiotix compare to Kiniksa Pharmaceuticals International?

Nanobiotix (NASDAQ:NBTX) and Kiniksa Pharmaceuticals International (NASDAQ:KNSA) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, media sentiment, risk, valuation, institutional ownership, analyst recommendations and earnings.

Kiniksa Pharmaceuticals International has a net margin of 9.59% compared to Nanobiotix's net margin of 0.00%. Kiniksa Pharmaceuticals International's return on equity of 13.65% beat Nanobiotix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nanobiotix	N/A	N/A	N/A
Kiniksa Pharmaceuticals International	9.59%	13.65%	10.09%

Nanobiotix has a beta of 0.81, indicating that its share price is 19% less volatile than the broader market. Comparatively, Kiniksa Pharmaceuticals International has a beta of 0.09, indicating that its share price is 91% less volatile than the broader market.

Nanobiotix presently has a consensus price target of $46.67, indicating a potential upside of 65.13%. Kiniksa Pharmaceuticals International has a consensus price target of $93.14, indicating a potential upside of 23.28%. Given Nanobiotix's higher probable upside, analysts plainly believe Nanobiotix is more favorable than Kiniksa Pharmaceuticals International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nanobiotix	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Kiniksa Pharmaceuticals International	0 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.78

Kiniksa Pharmaceuticals International has higher revenue and earnings than Nanobiotix.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nanobiotix	$36.87M	38.80	-$27.11M	N/A	N/A
Kiniksa Pharmaceuticals International	$677.56M	8.70	$59.01M	$0.97	77.89

In the previous week, Nanobiotix had 4 more articles in the media than Kiniksa Pharmaceuticals International. MarketBeat recorded 9 mentions for Nanobiotix and 5 mentions for Kiniksa Pharmaceuticals International. Kiniksa Pharmaceuticals International's average media sentiment score of 1.02 beat Nanobiotix's score of 0.31 indicating that Kiniksa Pharmaceuticals International is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nanobiotix	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Kiniksa Pharmaceuticals International	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

38.8% of Nanobiotix shares are held by institutional investors. Comparatively, 54.0% of Kiniksa Pharmaceuticals International shares are held by institutional investors. 3.5% of Nanobiotix shares are held by insiders. Comparatively, 52.0% of Kiniksa Pharmaceuticals International shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Kiniksa Pharmaceuticals International beats Nanobiotix on 10 of the 14 factors compared between the two stocks.

How does Nanobiotix compare to Scholar Rock?

Scholar Rock (NASDAQ:SRRK) and Nanobiotix (NASDAQ:NBTX) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and media sentiment.

Scholar Rock currently has a consensus price target of $66.75, indicating a potential upside of 40.79%. Nanobiotix has a consensus price target of $46.67, indicating a potential upside of 65.13%. Given Nanobiotix's higher possible upside, analysts clearly believe Nanobiotix is more favorable than Scholar Rock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scholar Rock	2 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	4 Strong Buy rating(s)	2.94
Nanobiotix	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Nanobiotix has higher revenue and earnings than Scholar Rock.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scholar Rock	N/A	N/A	-$377.94M	-$3.45	N/A
Nanobiotix	$36.87M	38.80	-$27.11M	N/A	N/A

In the previous week, Nanobiotix had 5 more articles in the media than Scholar Rock. MarketBeat recorded 9 mentions for Nanobiotix and 4 mentions for Scholar Rock. Scholar Rock's average media sentiment score of 0.46 beat Nanobiotix's score of 0.31 indicating that Scholar Rock is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Scholar Rock	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Nanobiotix	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

91.1% of Scholar Rock shares are owned by institutional investors. Comparatively, 38.8% of Nanobiotix shares are owned by institutional investors. 10.3% of Scholar Rock shares are owned by insiders. Comparatively, 3.5% of Nanobiotix shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Scholar Rock has a beta of 0.67, suggesting that its share price is 33% less volatile than the broader market. Comparatively, Nanobiotix has a beta of 0.81, suggesting that its share price is 19% less volatile than the broader market.

Nanobiotix's return on equity of 0.00% beat Scholar Rock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scholar Rock	N/A	-160.19%	-87.18%
Nanobiotix	N/A	N/A	N/A

Summary

Nanobiotix beats Scholar Rock on 7 of the 13 factors compared between the two stocks.

Get Nanobiotix News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NBTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NBTX vs. The Competition

Export

Metric	Nanobiotix	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.43B	$3.90B	$7.13B	$13.11B
Dividend Yield	N/A	3.63%	2.52%	14.40%
P/E Ratio	N/A	13.65	273.64	25.86
Price / Sales	38.80	1,297.80	656.97	105.97
Price / Cash	N/A	120.99	79.75	52.18
Price / Book	-14.35	15.73	10.54	6.28
Net Income	-$27.11M	-$22.67M	$3.50B	$360.95M
7 Day Performance	-15.54%	-2.53%	-2.04%	-1.67%
1 Month Performance	-28.07%	-8.50%	-5.21%	-3.19%
1 Year Performance	50.80%	24.12%	10.28%	2.93%

Nanobiotix Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NBTX Nanobiotix	2.6789 of 5 stars	$28.26 -9.3%	$46.67 +65.1%	+65.0%	$1.43B	$36.87M	N/A	97	Analyst Revision
CGON CG Oncology	2.9171 of 5 stars	$70.55 +1.4%	$87.78 +24.4%	+76.0%	$6.21B	$4.04M	N/A	142	Positive News
LGND Ligand Pharmaceuticals	3.2305 of 5 stars	$311.69 -0.8%	$337.89 +8.4%	+76.3%	$6.20B	$268.09M	33.26	47
GRAL GRAIL	0.8213 of 5 stars	$135.03 +1.8%	$85.60 -36.6%	+137.0%	$6.06B	$147.17M	N/A	910	Analyst Forecast
KNSA Kiniksa Pharmaceuticals International	4.2906 of 5 stars	$75.71 -0.5%	$91.29 +20.6%	+92.1%	$5.90B	$677.56M	78.02	366	Positive News Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NBTX) was last updated on 10/1/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Nanobiotix (NBTX) Competitors

NBTX vs. CGON, LGND, GRAL, KNSA, and SRRK

How does Nanobiotix compare to CG Oncology?

Summary

How does Nanobiotix compare to Ligand Pharmaceuticals?

Summary

How does Nanobiotix compare to GRAIL?

Summary

How does Nanobiotix compare to Kiniksa Pharmaceuticals International?

Summary

How does Nanobiotix compare to Scholar Rock?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NBTX vs. The Competition

Nanobiotix Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Nanobiotix (NBTX) Competitors

NBTX vs. CGON, LGND, GRAL, KNSA, and SRRK

How does Nanobiotix compare to CG Oncology?

Which has stronger earnings & valuation, CGON or NBTX?

Which has more risk & volatility, CGON or NBTX?

Does the media prefer CGON or NBTX?

Do insiders & institutionals hold more shares of CGON or NBTX?

Is CGON or NBTX more profitable?

Do analysts recommend CGON or NBTX?

Summary

How does Nanobiotix compare to Ligand Pharmaceuticals?

Which has more risk & volatility, LGND or NBTX?

Is LGND or NBTX more profitable?

Do institutionals and insiders believe in LGND or NBTX?

Which has stronger earnings & valuation, LGND or NBTX?

Does the media prefer LGND or NBTX?

Do analysts prefer LGND or NBTX?

Summary

How does Nanobiotix compare to GRAIL?

Which has more volatility and risk, GRAL or NBTX?

Which has higher earnings and valuation, GRAL or NBTX?

Do insiders & institutionals believe in GRAL or NBTX?

Does the media prefer GRAL or NBTX?

Do analysts prefer GRAL or NBTX?

Is GRAL or NBTX more profitable?

Summary

How does Nanobiotix compare to Kiniksa Pharmaceuticals International?

Is NBTX or KNSA more profitable?

Which has more volatility & risk, NBTX or KNSA?

Do analysts prefer NBTX or KNSA?

Which has stronger earnings & valuation, NBTX or KNSA?

Does the media favor NBTX or KNSA?

Do institutionals & insiders believe in NBTX or KNSA?

Summary

How does Nanobiotix compare to Scholar Rock?

Do analysts recommend SRRK or NBTX?

Which has higher earnings & valuation, SRRK or NBTX?

Does the media prefer SRRK or NBTX?

Do institutionals & insiders believe in SRRK or NBTX?

Which has more risk and volatility, SRRK or NBTX?

Is SRRK or NBTX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NBTX vs. The Competition

Nanobiotix Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools